Fate therapeutics reports fourth quarter and full year 2023 financial results and business updates

Cirm grant awarded to support phase 1 autoimmunity study of ft819 cd19-targeted car t-cell program for systemic lupus erythematosus; study start-up ongoing at multiple clinical sites

FATE Ratings Summary

FATE Quant Ranking